KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) EBT Margin (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed EBT Margin for 17 consecutive years, with 18.99% as the latest value for Q1 2026.

  • For Q1 2026, EBT Margin rose 2688.0% year-over-year to 18.99%; the TTM value through Mar 2026 reached 12.9%, up 3063.0%, while the annual FY2025 figure was 8.7%, 2549.0% up from the prior year.
  • EBT Margin hit 18.99% in Q1 2026 for Alnylam Pharmaceuticals, up from 7.86% in the prior quarter.
  • Across five years, EBT Margin topped out at 22.46% in Q3 2025 and bottomed at 153.59% in Q3 2022.
  • Average EBT Margin over 5 years is 37.24%, with a median of 21.69% recorded in 2024.
  • Year-over-year, EBT Margin plummeted -4474bps in 2022 and then skyrocketed 17367bps in 2023.
  • Alnylam Pharmaceuticals' EBT Margin stood at 61.79% in 2022, then skyrocketed by 49bps to 31.31% in 2023, then dropped by -4bps to 32.7% in 2024, then surged by 124bps to 7.86% in 2025, then skyrocketed by 142bps to 18.99% in 2026.
  • According to Business Quant data, EBT Margin over the past three periods came in at 18.99%, 7.86%, and 22.46% for Q1 2026, Q4 2025, and Q3 2025 respectively.